Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Parameters associated with significant liver histological changes in patients with chronic hepatitis B.

Xiao L, Xian J, Li Y, Geng A, Yang X, Han L, Xu H.

ISRN Gastroenterol. 2014 Jan 28;2014:913890. doi: 10.1155/2014/913890. eCollection 2014.

2.

Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.

Liu XD, Wu JL, Liang J, Zhang T, Sheng QS.

World J Gastroenterol. 2012 Jun 14;18(22):2784-92. doi: 10.3748/wjg.v18.i22.2784.

3.

Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?

Vardar R, Vardar E, Demiri S, Sayhan SE, Bayol U, Yildiz C, Postaci H.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1459-65.

PMID:
19950810
4.

Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B.

Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ.

World J Gastroenterol. 2007 Apr 14;13(14):2104-7.

5.

Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT.

Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J.

PLoS One. 2013 Oct 25;8(10):e78672. doi: 10.1371/journal.pone.0078672. eCollection 2013.

6.
7.

 Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients.

Esmaeelzadeh A, Saadatnia H, Memar B, Mokhtari Amirmajdi E, Ganji A, Goshayeshi L, Meshkat Z, Pasdar A, Vosoughinia H, Farzanehfar M, Tehranian S, Ghaffarzadehgan K, Rajabzadeh F, Ahadi M.

Gastroenterol Hepatol Bed Bench. 2017 Winter;10(1):39-43.

8.

[Differential liver histopathological features of chronic HBV infection patients with normal and mildly elevated serum ALT].

Ying RS, Yang Z, Chen YY, Yang KL, Xiao YH, Wu LJ, Fan HM.

Zhonghua Gan Zang Bing Za Zhi. 2012 Aug;20(8):585-8. doi: 10.3760/cma.j.issn.1007-3418.2012.08.009. Chinese.

PMID:
23207151
9.

Predictors of Liver Disease Severity in Children with Chronic Hepatitis B.

Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Walewska-Zielecka B, Marczyńska M.

Adv Clin Exp Med. 2016 Jul-Aug;25(4):681-8. doi: 10.17219/acem/60535.

10.

The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis.

Zhang M, Wu R, Jiang J, Minuk GY, Niu J.

Alcohol. 2013 Nov;47(7):553-8. doi: 10.1016/j.alcohol.2013.07.003. Epub 2013 Sep 13.

PMID:
24041840
11.

A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B.

Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF.

PLoS One. 2011;6(8):e23077. doi: 10.1371/journal.pone.0023077. Epub 2011 Aug 11.

12.

The utility of thrombopoietin in predicting liver fibrosis in chronic hepatitis B.

Yilmaz B, Basar O, Altınbas A, Ekiz F, Aktas B, Oztürk G, Ginis Z, Coban S, Ucar E, Erarslan E, Coskun Y, Yüksel I, Tuna Y, Yüksel O.

Int J Clin Exp Med. 2014 May 15;7(5):1430-4. eCollection 2014.

13.

Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B.

Yim SY, Um SH, Young Jung J, Kim TH, Kim JD, Keum B, Seo YS, Yim HJ, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.

J Clin Gastroenterol. 2015 Jan;49(1):61-8. doi: 10.1097/MCG.0000000000000052.

PMID:
24406435
14.

HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication.

Praneenararat S, Chamroonkul N, Sripongpun P, Kanngurn S, Jarumanokul R, Piratvisuth T.

BMC Gastroenterol. 2014 Dec 19;14:218. doi: 10.1186/s12876-014-0218-6.

15.

Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease.

Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, Li YB, Chen J, Zheng Q, Jiang JJ, Dong J.

PLoS One. 2013 Oct 25;8(10):e77942. doi: 10.1371/journal.pone.0077942. eCollection 2013.

16.

Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B.

Croagh CM, Bell SJ, Slavin J, Kong YX, Chen RY, Locarnini S, Desmond PV.

Liver Int. 2010 Sep;30(8):1115-22. doi: 10.1111/j.1478-3231.2010.02267.x. Epub 2010 May 21.

PMID:
20492511
17.

Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.

Ormeci A, Aydın Y, Sumnu A, Baran B, Soyer OM, Pınarbasi B, Gokturk S, Gulluoglu M, Onel D, Badur S, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S.

Int J Infect Dis. 2016 Nov;52:68-73. doi: 10.1016/j.ijid.2016.09.007. Epub 2016 Sep 9.

18.

Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B.

Zeng X, Xu C, He D, Li M, Zhang H, Wu Q, Xiang D, Wang Y.

Croat Med J. 2015 Jun;56(3):272-9.

19.

[Relationship between hepatitis B surface antigen, HBV DNA quantity and liver fibrosis severity].

Gao Y, Zou G, Ye J, Pan G, Rao J, Li F, Wei Y, Li X.

Zhonghua Gan Zang Bing Za Zhi. 2015 Apr;23(4):254-7. doi: 10.3760/cma.j.issn.1007-3418.2015.04.005. Chinese.

PMID:
26133815
20.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721

Supplemental Content

Support Center